{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T05:01:47Z","timestamp":1794718907569,"version":"4.9.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2011,6,7]],"date-time":"2011-06-07T00:00:00Z","timestamp":1307404800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1007\/s00415-011-6116-8","type":"journal-article","created":{"date-parts":[[2011,6,6]],"date-time":"2011-06-06T21:53:07Z","timestamp":1307397187000},"page":"1920-1928","source":"Crossref","is-referenced-by-count":66,"title":["Progressive multifocal leukoencephalopathy and natalizumab"],"prefix":"10.1007","volume":"258","author":[{"given":"Kerstin","family":"Hellwig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,6,7]]},"reference":[{"key":"6116_CR1","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJMp068005","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:889\u2013910","journal-title":"N Engl J Med"},{"key":"6116_CR2","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1212\/01.wnl.0000260064.77700.fd","volume":"68","author":"DH Miller","year":"2007","unstructured":"Miller DH, Soon D, Fernando KT et al (2007) MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 68:1390\u20131401","journal-title":"Neurology"},{"issue":"Suppl 1","key":"6116_CR3","first-page":"S168","volume":"14","author":"F Munschauer","year":"2008","unstructured":"Munschauer F, Giovannoni G, Lublin F et al (2008) Natalizumab significantly increases the cumulative probability of sustained improvement in physical disability. Mult Scler 14(Suppl 1):S168","journal-title":"Mult Scler"},{"key":"6116_CR4","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00415-009-0093-1","volume":"256","author":"M Hutchinson","year":"2009","unstructured":"Hutchinson M, Kappos L, Calabresi PA, For the AFFIRM and SENTINEL Investigators et al (2009) The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol 256:405\u2013415","journal-title":"J Neurol"},{"key":"6116_CR5","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1474-4422(09)70021-3","volume":"8","author":"E Havrdova","year":"2009","unstructured":"Havrdova E, Galetta S, Hutchinson M et al (2009) Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 8:254\u2013260","journal-title":"Lancet Neurol"},{"key":"6116_CR6","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1212\/01.wnl.0000259521.14704.a8","volume":"68","author":"L Balcer","year":"2007","unstructured":"Balcer L, Galetta S, Calabresi P et al (2007) Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology 68:1299\u20131304","journal-title":"Neurology"},{"key":"6116_CR7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/ana.21163","volume":"62","author":"R Rudick","year":"2007","unstructured":"Rudick R, Miller D, Hass S et al (2007) Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 62:335\u2013346","journal-title":"Ann Neurol"},{"key":"6116_CR8","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","volume":"353","author":"BK Kleinschmidt-DeMasters","year":"2005","unstructured":"Kleinschmidt-DeMasters BK, Tyler KL (2005) Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353:369\u2013374","journal-title":"N Engl J Med"},{"key":"6116_CR9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","volume":"353","author":"A Langer-Gould","year":"2005","unstructured":"Langer-Gould A, Atlas SW, Green AJ et al (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353:375\u2013381","journal-title":"N Engl J Med"},{"key":"6116_CR10","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","volume":"353","author":"G Assche Van","year":"2005","unstructured":"Van Assche G, Van Ranst M, Sciot R et al (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn\u2019s disease. N Engl J Med 353:362\u2013368","journal-title":"N Engl J Med"},{"key":"6116_CR11","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa054693","volume":"354","author":"T Yousry","year":"2006","unstructured":"Yousry T, Major E, Ryschkewitsch C et al (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354:924\u2013933","journal-title":"N Engl J Med"},{"key":"6116_CR12","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","volume":"354","author":"RA Rudick","year":"2006","unstructured":"Rudick RA, Stuart WH, Calabresi PA et al (2006) Natalizumab plus interferon beta-1 for relapsing multiple sclerosis. N Eng J Med 354:911\u2013923","journal-title":"N Eng J Med"},{"key":"6116_CR13","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","volume":"9","author":"DB Clifford","year":"2010","unstructured":"Clifford DB, De Luca A, Simpson DW et al (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons learned from 28 cases. Lancet Neurol 9:438\u2013446","journal-title":"Lancet Neurol"},{"issue":"11","key":"6116_CR14","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1001\/archneurol.2010.157","volume":"67","author":"A Schr\u00f6der","year":"2010","unstructured":"Schr\u00f6der A, Lee DH, Hellwig K et al (2010) Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis. Arch Neurol 67(11):1391\u20131394","journal-title":"Arch Neurol"},{"key":"6116_CR15","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","volume":"68","author":"L Gorelik","year":"2010","unstructured":"Gorelik L, Lerner M, Bixler S et al (2010) Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 68:295\u2013303","journal-title":"Ann Neurol"},{"key":"6116_CR16","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ncl.2008.03.007","volume":"26","author":"T Weber","year":"2008","unstructured":"Weber T (2008) Progressive multifocal leukoencephalopathy. Neurol Clin 26:833\u2013854","journal-title":"Neurol Clin"},{"issue":"9","key":"6116_CR17","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.3174\/ajnr.A2035","volume":"31","author":"AK Bag","year":"2010","unstructured":"Bag AK, Cur\u00e9 JK, Chapman PR, Roberson GH, Shah R (2010) JC virus infection of the brain. AJNR Am J Neuroradiol 31(9):1564\u20131576","journal-title":"AJNR Am J Neuroradiol"},{"key":"6116_CR18","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1002\/art.22657","volume":"56","author":"LH Calabrese","year":"2007","unstructured":"Calabrese LH, Molloy ES, Huang DR, Ransohoff RM (2007) Progressive multifocal leukoencephalopathy in rheumatic diseases. Arthritis Rheum 56:2116\u20132128","journal-title":"Arthritis Rheum"},{"key":"6116_CR19","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(09)70161-5","volume":"10","author":"KR Carson","year":"2009","unstructured":"Carson KR, Focosi D, Major EO et al (2009) Monoclonal antibody-associated progressive multifocal leukoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 10:816\u2013824","journal-title":"Lancet Oncol"},{"issue":"Pt 9","key":"6116_CR20","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1099\/vir.0.81945-0","volume":"87","author":"X Dang","year":"2006","unstructured":"Dang X, Koralnik IJ (2006) A granule cell neuron-associated JC virus variant has a unique deletion in the VP1 gene. J Gen Virol 87(Pt 9):2533\u20132537","journal-title":"J Gen Virol"},{"issue":"6","key":"6116_CR21","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/ana.21619","volume":"65","author":"C W\u00fcthrich","year":"2009","unstructured":"W\u00fcthrich C, Dang X, Westmoreland S, McKay J, Maheshwari A, Anderson MP, Ropper AH, Viscidi RP, Koralnik IJ (2009) Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons. Ann Neurol 65(6):742\u2013748","journal-title":"Ann Neurol"},{"issue":"2","key":"6116_CR22","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1212\/01.wnl.0000194227.16696.11","volume":"66","author":"MA Lima","year":"2006","unstructured":"Lima MA, Drislane FW, Koralnik IJ (2006) Seizures and their outcome in progressive multifocal leukoencephalopathy. Neurology 66(2):262\u2013264","journal-title":"Neurology"},{"key":"6116_CR23","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1089\/aid.2006.0252","volume":"24","author":"ML Giancola","year":"2008","unstructured":"Giancola ML, Rizzi EB, Lorenzini P et al (2008) Progressive multifocal leukoencephalopathy in HIV-infected patients in the era of HAART: radiological features at diagnosis and follow-up and correlation with clinical variables. AIDS Res Hum Retroviruses 24:155\u2013162","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"8","key":"6116_CR24","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1001\/archneurol.2010.161","volume":"67","author":"C Warnke","year":"2010","unstructured":"Warnke C, Menge T, Hartung HP, Racke MK, Cravens PD, Bennett JL, Frohman EM, Greenberg BM, Zamvil SS, Gold R, Hemmer B, Kieseier BC, St\u00fcve O (2010) Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol 67(8):923\u2013930 Review","journal-title":"Arch Neurol"},{"key":"6116_CR25","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1056\/NEJMoa0904267","volume":"361","author":"Y Chen","year":"2009","unstructured":"Chen Y, Bord E, Tompkins T et al (2009) Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 361:1067\u20131074","journal-title":"N Engl J Med"},{"issue":"12","key":"6116_CR26","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1136\/jnnp.2009.201079","volume":"81","author":"L Rinaldi","year":"2010","unstructured":"Rinaldi L, Rinaldi F, Perini P, Calabrese M, Seppi D, Grossi P, Mattisi I, Barzon L, Mengoli C, Sanzari M, Pal\u00fa G, Gallo P (2010) No evidence of JC virus reactivation in natalizumab-treated multiple sclerosis patients: an 18\u00a0month follow-up study. J Neurol Neurosurg Psychiatry 81(12):1345\u20131350","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"6116_CR27","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.1182\/blood-2007-10-120329","volume":"111","author":"F Zohren","year":"2008","unstructured":"Zohren F, Toutzaris D, Kl\u00e4rner V, Hartung HP, Kieseier B, Haas R (2008) The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 111(7):3893\u20133895","journal-title":"Blood"},{"issue":"2","key":"6116_CR28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/1352458510385834","volume":"17","author":"C Warnke","year":"2011","unstructured":"Warnke C, Smolianov V, Dehmel T, Andr\u00e9e M, Hengel H, Zohren F, Arendt G, Wiendl H, Haas R, Hartung HP, Adams O, Kieseier BC (2011) CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus. Mult Scler 17(2):151\u2013156","journal-title":"Mult Scler"},{"issue":"4","key":"6116_CR29","doi-asserted-by":"crossref","first-page":"e18506","DOI":"10.1371\/journal.pone.0018506","volume":"6","author":"A Haghikia","year":"2011","unstructured":"Haghikia A, Perrech M, Pula B, Ruhrmann S, Potthoff A, Brockmeyer NH, Goelz S, Wiendl H, Lind\u00e5 H, Ziemssen T, Baranzini SE, K\u00e4ll T-B, Bengel D, Olsson T, Gold R, Chan A (2011) Functional energetics of CD4+ -cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders. PLoS One 6(4):e18506","journal-title":"PLoS One"},{"key":"6116_CR30","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1212\/WNL.52.3.623","volume":"52","author":"DB Clifford","year":"1999","unstructured":"Clifford DB, Yiannoutsos C, Glicksman M et al (1999) HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology 52:623\u2013625","journal-title":"Neurology"},{"key":"6116_CR31","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1086\/315817","volume":"182","author":"A DeLuca","year":"2000","unstructured":"DeLuca A, Giancola ML, Annassari A et al (2000) The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy. J Infect Dis 182:1077\u20131083","journal-title":"J Infect Dis"},{"issue":"5","key":"6116_CR32","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1128\/AAC.01614-08","volume":"53","author":"M Brickelmaier","year":"2009","unstructured":"Brickelmaier M, Lugovskoy A, Kartikeyan R, Reviriego-Mendoza MM, Allaire N, Simon K, Frisque RJ, Gorelik L (2009) Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother 53(5):1840\u20131849","journal-title":"Antimicrob Agents Chemother"},{"key":"6116_CR33","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJM199805073381903","volume":"338","author":"CD Hall","year":"1998","unstructured":"Hall CD, Dafni U, Simpson D et al (1998) AIDS Clinical Trials Group 243 Team. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. N Engl J Med 338:1345\u20131351","journal-title":"N Engl J Med"},{"key":"6116_CR34","doi-asserted-by":"crossref","first-page":"F117","DOI":"10.1097\/00002030-200009290-00001","volume":"14","author":"A DeLuca","year":"2000","unstructured":"DeLuca A, Giancola ML, Ammassari A et al (2000) Cidofovir added to HAART improved virological and clinical outcome in AIDS-associated progressive multifocal leukoencephalopathy. AIDS 14:F117\u2013F121","journal-title":"AIDS"},{"key":"6116_CR35","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1080\/13550280152537256","volume":"7","author":"A DeLuca","year":"2001","unstructured":"DeLuca A, Giancola ML, Ammassari A et al (2001) Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: extended follow-up of an observational study. J Neurovirol 7:364\u2013368","journal-title":"J Neurovirol"},{"key":"6116_CR36","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/sj.bmt.1701010","volume":"20","author":"D Przepiorka","year":"1997","unstructured":"Przepiorka D, Jaeckle KA, Birdwell RR et al (1997) Successful treatment of progressive multifocal leukoencephalopathy with low-dose interleukin-2. Bone Marrow Transplant 20:983\u2013987","journal-title":"Bone Marrow Transplant"},{"key":"6116_CR37","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/sj.bmt.1701568","volume":"23","author":"D Re","year":"1999","unstructured":"Re D, Bamborschke S, Feiden W et al (1999) Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy. Bone Marrow Transplant 23:295\u2013298","journal-title":"Bone Marrow Transplant"},{"key":"6116_CR38","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3109\/13550289809114533","volume":"4","author":"SS Huang","year":"1998","unstructured":"Huang SS, Skolasky RL, Dal Pan GJ et al (1998) Survival prolongation in HIV-associated progressive multifocal leukoencephalopathy treated with alpha-interferon: an observational study. J Neurovirol 4:324\u2013332","journal-title":"J Neurovirol"},{"key":"6116_CR39","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/13550280152537238","volume":"7","author":"MD Geschwind","year":"2001","unstructured":"Geschwind MD, Skolasky RI, Royal WS, McArthur JC (2001) The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS. J Neurovirol 7:353\u2013357","journal-title":"J Neurovirol"},{"key":"6116_CR40","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1212\/01.wnl.0000191322.93310.a1","volume":"66","author":"A Nath","year":"2006","unstructured":"Nath A, Venkataramana A, Reich DS et al (2006) Progression of progressive multifocal leukoencephalopathy despite treatment with \u03b2-interferon. Neurology 66:149\u2013150","journal-title":"Neurology"},{"key":"6116_CR41","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1212\/01.wnl.0000183064.10227.b5","volume":"65","author":"L Kunschner","year":"2005","unstructured":"Kunschner L, Scott TF (2005) Sustained recovery of progressive multifocal leukoencephalopathy after treatment with IL-2. Neurology 65:1510","journal-title":"Neurology"},{"issue":"3","key":"6116_CR42","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1212\/01.wnl.0000227922.22293.93","volume":"67","author":"A Venkataramana","year":"2006","unstructured":"Venkataramana A, Pardo CA, McArthur JC, Kerr DA, Irani DN, Griffin JW, Burger P, Reich DS, Calabresi PA, Nath A (2006) Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients. Neurology 67(3):383\u2013388","journal-title":"Neurology"},{"key":"6116_CR43","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1212\/01.wnl.0000343510.08643.74","volume":"72","author":"K Tan","year":"2009","unstructured":"Tan K, Roda R, Ostrow L et al (2009) PML-IRIS in HIV infection. Clinical manifestations and treatment with steroids. Neurology 72:1458\u20131464","journal-title":"Neurology"},{"key":"6116_CR44","unstructured":"Biogen Idec. Data on file"},{"issue":"suppl 10","key":"6116_CR45","first-page":"S315","volume":"16","author":"C Bozic","year":"2010","unstructured":"Bozic C, Christiano LM, Hyde R et al (2010) Utilisation and safety of natalizumab in patients with relapsing multiple sclerosis. Mult Scler 16(suppl 10):S315","journal-title":"Mult Scler"},{"issue":"suppl 2","key":"6116_CR46","first-page":"S234","volume":"15","author":"M Stangel","year":"2009","unstructured":"Stangel M, Sorensen PS, Petersen T et al (2009) Natalizumab utilization and safety in the TYGRIS program in the European Union and Canada. Mult Scler 15(suppl 2):S234","journal-title":"Mult Scler"},{"key":"6116_CR47","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/01.wnl.0000341766.59028.9d","volume":"72","author":"B Khatri","year":"2009","unstructured":"Khatri B, Man S, Giovannoni G et al (2009) Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 72:402\u2013409","journal-title":"Neurology"},{"key":"6116_CR48","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJMoa0810257","volume":"361","author":"W Wenning","year":"2009","unstructured":"Wenning W, Haghikia A, Laubenberger M et al (2009) Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 361:1075\u20131080","journal-title":"N Engl J Med"},{"issue":"3","key":"6116_CR49","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/ana.22137","volume":"68","author":"CF Ryschkewitsch","year":"2010","unstructured":"Ryschkewitsch CF, Jensen PN, Monaco MC, Major EO (2010) JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab. Ann Neurol 68(3):384\u2013391","journal-title":"Ann Neurol"},{"issue":"20","key":"6116_CR50","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","volume":"113","author":"KR Carson","year":"2009","unstructured":"Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major EO, Bennett CL (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113(20):4834\u20134840","journal-title":"Blood"},{"issue":"suppl 2","key":"6116_CR51","first-page":"S240","volume":"15","author":"PW O\u2019Connor","year":"2009","unstructured":"O\u2019Connor PW, Goodman A, Kappos L et al (2009) Return of disease activity with cessation of natalizumab therapy in patients with multiple sclerosis. Mult Scler 15(suppl 2):S240\u2013S243","journal-title":"Mult Scler"},{"key":"6116_CR52","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/ana.22074","volume":"68","author":"J Killestein","year":"2010","unstructured":"Killestein J, Vennegoor A, Strijbis EM et al (2010) Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol 68:392\u2013395","journal-title":"Ann Neurol"},{"key":"6116_CR53","unstructured":"Clinicaltrials.gov Web site (2010) Trial NCT00746941. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01071083?term=biogen+idec+restore&rank=1 . Accessed 9 November 2010"},{"key":"6116_CR54","unstructured":"European Agency for the Evaluation of Medicinal Products (2010) TYSABRI\u00ae summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000603\/WC500044686.pdf . Accessed 19 August 2010"},{"key":"6116_CR55","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1474-4422(07)70078-9","volume":"6","author":"L Kappos","year":"2007","unstructured":"Kappos L, Bates D, Hartung HP et al (2007) Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 6:431\u2013444","journal-title":"Lancet Neurol"},{"issue":"5","key":"6116_CR56","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue EW, O\u2019Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362(5):387\u2013401","journal-title":"N Engl J Med"},{"key":"6116_CR57","unstructured":"Kappos L, Bates D, Edan G et al (2011) Natalizumab in patients with multiple sclerosis: treatment recommendations. Lancet Neurol (in press)"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-011-6116-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-011-6116-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-011-6116-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T19:13:09Z","timestamp":1559070789000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-011-6116-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,7]]},"references-count":57,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["6116"],"URL":"https:\/\/doi.org\/10.1007\/s00415-011-6116-8","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,7]]}}}